These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 27251130)

  • 41. Bodyweight gain with atypical antipsychotics. A comparative review.
    Wetterling T
    Drug Saf; 2001 Jan; 24(1):59-73. PubMed ID: 11219487
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs.
    Wang LJ; Ree SC; Huang YS; Hsiao CC; Chen CK
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jan; 40():260-6. PubMed ID: 23085073
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of naltrexone on food intake and body weight gain in olanzapine-treated rats.
    Kurbanov DB; Currie PJ; Simonson DC; Borsook D; Elman I
    J Psychopharmacol; 2012 Sep; 26(9):1244-51. PubMed ID: 22723540
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Betahistine effects on weight-related measures in patients treated with antipsychotic medications: a double-blind placebo-controlled study.
    Smith RC; Maayan L; Wu R; Youssef M; Jing Z; Sershen H; Szabo V; Meyers J; Jin H; Zhao J; Davis JM
    Psychopharmacology (Berl); 2018 Dec; 235(12):3545-3558. PubMed ID: 30382354
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of olanzapine in male rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabolic abnormalities.
    Cooper GD; Pickavance LC; Wilding JP; Harrold JA; Halford JC; Goudie AJ
    J Psychopharmacol; 2007 Jun; 21(4):405-13. PubMed ID: 17050655
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mechanisms underlying metabolic disturbances associated with psychosis and antipsychotic drug treatment.
    Reynolds GP; McGowan OO
    J Psychopharmacol; 2017 Nov; 31(11):1430-1436. PubMed ID: 28892404
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Recent evidence and potential mechanisms underlying weight gain and insulin resistance due to atypical antipsychotics.
    Volpato AM; Zugno AI; Quevedo J
    Braz J Psychiatry; 2013; 35(3):295-304. PubMed ID: 24142093
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Atypical antipsychotics and weight gain.
    Postgrad Med; 2003 Dec; 114(6 Suppl Managing Metabolic):46-58. PubMed ID: 19667655
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Obestatin reduces food intake and suppresses body weight gain in rodents.
    Lagaud GJ; Young A; Acena A; Morton MF; Barrett TD; Shankley NP
    Biochem Biophys Res Commun; 2007 May; 357(1):264-9. PubMed ID: 17418097
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The atypical antipsychotic olanzapine enhances ingestive behaviour in the rat: a preliminary study.
    Thornton-Jones Z; Neill JC; Reynolds GP
    J Psychopharmacol; 2002 Mar; 16(1):35-7. PubMed ID: 11949769
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Olanzapine and food craving: a case control study.
    Abbas MJ; Liddle PF
    Hum Psychopharmacol; 2013 Jan; 28(1):97-101. PubMed ID: 23169487
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term treatment with atypical antipsychotics and the risk of weight gain : a literature analysis.
    Gentile S
    Drug Saf; 2006; 29(4):303-19. PubMed ID: 16569080
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment.
    Hong CJ; Liou YJ; Bai YM; Chen TT; Wang YC; Tsai SJ
    Pharmacogenet Genomics; 2010 Jun; 20(6):359-66. PubMed ID: 20375926
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Investigation into the influence of a high fat diet on antipsychotic-induced weight gain in female rats.
    Fell MJ; Neill JC; Anjum N; Peltola LM; Marshall KM
    J Psychopharmacol; 2008 Mar; 22(2):182-6. PubMed ID: 18308803
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of atypical antipsychotic drugs on body weight and food intake in dopamine D2 receptor knockout mice.
    Yoon S; Noh JS; Choi SY; Baik JH
    Biochem Biophys Res Commun; 2010 Mar; 393(2):235-41. PubMed ID: 20117094
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Which comes first: atypical antipsychotic treatment or cardiometabolic risk?
    Stahl SM; Mignon L; Meyer JM
    Acta Psychiatr Scand; 2009 Mar; 119(3):171-9. PubMed ID: 19178394
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dietary intake and eating behavior in depot medroxyprogesterone acetate users: a systematic review.
    Silva P; Qadir S; Fernandes A; Bahamondes L; Peipert JF
    Braz J Med Biol Res; 2018; 51(6):e7575. PubMed ID: 29694506
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Structural contributions of antipsychotic drugs to their therapeutic profiles and metabolic side effects.
    Jafari S; Fernandez-Enright F; Huang XF
    J Neurochem; 2012 Feb; 120(3):371-84. PubMed ID: 22103329
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities.
    McIntyre RS; McCann SM; Kennedy SH
    Can J Psychiatry; 2001 Apr; 46(3):273-81. PubMed ID: 11320682
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Review of atypical antipsychotics and weight gain.
    Sussman N
    J Clin Psychiatry; 2001; 62 Suppl 23():5-12. PubMed ID: 11603886
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.